Everyone Is Talking About NAD+.
Here’s What It Actually Does Inside Your Cells.

NAD+ has gone from an obscure molecule in biochemistry textbooks to one of the most talked-about compounds in longevity. But somewhere between the laboratory and social media, the explanation got messy.

NAD+ IV clinics promise rejuvenation. Supplements promise energy. Longevity conversations routinely describe it as something we “lose” as we age.

NAD+ is not a stimulant. It is not a youth hormone. And increasing NAD+ does not automatically mean that a person will live longer, think faster or reverse aging.

What NAD+ actually does inside the body is more fundamental — and arguably more interesting.

Understanding that biology is the best place to start.

NAD+ stands for nicotinamide adenine dinucleotide.

The name is intimidating. The basic idea isn't.

Inside cells, thousands of chemical reactions are happening continuously. Nutrients from food have to be broken down, energy has to be transferred, damaged molecules have to be dealt with, DNA has to be maintained and cells have to constantly respond to their environment.

NAD+ participates in many of these processes.

One of its oldest and best-understood jobs is acting as a redox coenzyme — essentially helping transfer electrons from one molecule to another.

This matters because extracting energy from carbohydrates, fats and proteins depends on a chain of electron-transfer reactions.

NAD+ accepts electrons and becomes its reduced form, NADH. NADH can then carry those electrons into other metabolic processes, including mitochondrial energy production.

ATP is the form of chemical energy cells can readily use.

This doesn't mean NAD+ is “energy” itself. It means NAD+ is part of the machinery that allows energy metabolism to happen.

The story became much more interesting when researchers discovered that NAD+ isn't only moving electrons around.

Several important families of enzymes consume NAD+ as part of their activity.

In other words, NAD+ sits at an unusual intersection:

That is a major reason longevity researchers became so interested in it.

This is where the story needs some nuance.

You have probably seen a graph online that looks something like this:

There is biological evidence that NAD+ availability changes with age, and declines have been observed in multiple animal models and in some human tissues.

But the popular version of the story is more certain than the human evidence currently allows.

A major 2025 review in Nature Metabolism examined the evidence specifically in humans and reached a much more cautious conclusion: consistent age-associated NAD+ decline has been demonstrated in only a limited number of human studies, and data across different tissues remain sparse.

An earlier critical review reached a similar conclusion: while NAD+ decline with age is frequently presented as universal, the human evidence is still surprisingly limited and often tissue-specific.

That distinction matters.

NAD+ also exists in different cellular compartments, and measuring a molecule in blood does not necessarily tell us exactly what's happening inside every tissue.

So the scientifically responsible statement isn't:

“Everyone's NAD+ collapses as they get older.”

It's:

That's less dramatic.

It's also much closer to the science.

Researchers are investigating several mechanisms.

One possibility is reduced production.

Another is increased consumption.

For example, enzymes including PARPs and CD38 consume NAD+. Processes associated with aging — including cellular damage and chronic inflammatory signaling — may alter the balance between how quickly NAD+ is produced and how quickly it is used.

Researchers increasingly talk about NAD+ homeostasis rather than simply “NAD+ levels.”

That's an important distinction.

The question isn't simply how much exists.

It's whether that entire system remains balanced.

This may be the single biggest misconception in consumer marketing.

Because NAD+ participates in cellular energy metabolism, it's tempting to translate that into:

Biochemistry doesn't work that neatly.

Caffeine can have noticeable effects because it interacts with adenosine receptors in the nervous system.

NAD+ operates much further down in basic cellular metabolism.

Supporting cellular energy metabolism is therefore not the same thing as producing a stimulant rush.

A person shouldn't interpret the absence of a caffeine-like feeling as evidence that nothing biological is happening — nor should they assume that feeling more energetic proves their NAD+ levels increased.

Subjective energy and cellular NAD+ are different measurements.

This is where the research gets particularly interesting.

Most human research has not involved swallowing NAD+ itself.

Instead, researchers have focused heavily on NAD+ precursors — compounds the body can use to synthesize NAD+.

Two of the most discussed are:

Numerous human trials have shown that these compounds can alter NAD-related biomarkers.

A 2026 systematic review evaluated 33 human intervention studies involving NAD-related approaches.

The overall picture was interesting but mixed.

NR and NMN generally demonstrated biochemical target engagement — meaning researchers could measure changes in NAD-related metabolites or biomarkers.

But effects on outcomes such as metabolism, vascular function, physical performance and other healthspan-related measures were heterogeneous and frequently absent or specific to particular endpoints.

Both things matter.

They're simply not the same thing.

For a long time, direct oral NAD+ received much less human research than its precursors.

One reason is biological.

NAD+ is a relatively large molecule, and scientists have debated how intact NAD+ behaves after oral administration, how much reaches circulation, how it is metabolized and whether different formulations behave differently.

In 2026, researchers reported a randomized, double-blind, placebo-controlled study in healthy adults aged 45–75 investigating a specific oral formulation called LathMized NAD+.

Sixty participants were randomized, with 50 included in the primary analysis.

That's an intriguing result.

But here's the part supplement marketing could easily leave out:

This was a proprietary, physically modified NAD+ formulation.

It does not establish that every oral NAD+ product will produce the same result.

And the trial was short.

The authors reported that none of the secondary clinical, wellbeing, vital-sign or wearable-derived outcomes survived statistical correction for multiple comparisons.

So what did the study actually establish?

Those are very different claims.

The biology surrounding NAD+ is compelling.

Animal research has produced remarkable findings.

Human researchers can increasingly demonstrate that certain interventions alter NAD+ metabolism.

Yet the ultimate questions people care about are much bigger:

For those questions, the evidence isn't finished.

A contemporary review of human NAD+ supplementation research describes clinical efficacy as limited despite strong preclinical evidence.

And that is not a failure of the science.

That's science doing what it is supposed to do.

Separate what is biologically plausible from what has actually been demonstrated.

Quite the opposite.

There is a tendency in wellness to think something must be either:

Biology rarely works that way.

NAD+ is unquestionably important.

It participates in fundamental metabolic reactions.

It interacts with enzymes involved in important cellular processes.

Its metabolism appears to change with age and disease.

And researchers can manipulate NAD-related pathways in humans.

Those facts alone make NAD+ a legitimate and important area of aging research.

The unresolved question is not:

“Does NAD+ matter?”

It clearly does.

The question is:

That's a much harder question.

And it's the one worth answering.

When we developed AGE BACK, we didn't want to build the formula around the idea that one molecule could “reverse aging.”

That wouldn't reflect the biology.

Instead, the formula approaches healthy aging from several nutritional angles.